National Research (NASDAQ:NRC) Price Target Raised to $27.00

National Research (NASDAQ:NRC) had its price target increased by investment analysts at Citizens Jmp from $26.00 to $27.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage presently has a “market outperform” rating on the stock. Citizens Jmp‘s target price suggests a potential upside of 24.14% from the stock’s previous close.

Other research analysts also recently issued research reports about the stock. Weiss Ratings downgraded shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 9th. Zacks Research raised National Research to a “hold” rating in a report on Monday, October 5th. Finally, Wall Street Zen lowered National Research from a “buy” rating to a “hold” rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $27.00.

National Research Price Performance

NASDAQ:NRC opened at $21.75 on Wednesday. The stock has a 50-day simple moving average of $21.12 and a two-hundred day simple moving average of $19.15. National Research has a 52-week low of $11.43 and a 52-week high of $23.68.

National Research (NASDAQ:NRC) last released its earnings results on Tuesday, October 27th. The company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.03. The firm had revenue of $38.40 million for the quarter, compared to the consensus estimate of $35.80 million. As a group, equities analysts predict that National Research will post 0.98 earnings per share for the current year.

Institutional Trading of National Research

A number of large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its holdings in shares of National Research by 3.0% during the 1st quarter. Bank of America Corp DE now owns 112,468 shares of the company’s stock worth $1,910,000 after acquiring an additional 3,323 shares in the last quarter. Bank of New York Mellon Corp raised its position in National Research by 4.0% during the first quarter. Bank of New York Mellon Corp now owns 250,707 shares of the company’s stock valued at $4,257,000 after purchasing an additional 9,730 shares during the period. Hsbc Holdings PLC purchased a new stake in National Research during the first quarter valued at approximately $180,000. Empowered Funds LLC bought a new position in shares of National Research during the 1st quarter valued at approximately $226,000. Finally, Empirical Finance LLC purchased a new position in shares of National Research during the 2nd quarter worth about $431,000. Institutional investors own 47.26% of the company’s stock.

National Research Company Profile

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.

Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.